NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare ...(tions that theCompany believes offers si...)

Date:11/10/2008

tions, that the Company believes offers significant advantages over other pain therapies. NeurogesX submitted a new drug application (NDA) for NGX-4010 with the U.S. Food and Drug Administration (FDA) in October 2008 for PHN, which is subject to acceptance by the FDA. Additionally, a marketing authorization application (MAA) for NGX-4010 seeking approval for peripheral neuropathic pain is currently under review by the European Medicines Agency (EMEA).

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 is currently in Phase 1 development.

NeurogesX' early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the potential markets for NeurogesX' product candidates; the expected benefits of NeurogesX' product candidates; and its plans with regard to seeking potential development partners for its early stage product pipeline. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European re
'/>"/>

SOURCE NeurogesX, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. NeurogesX Reports Third Quarter 2008 Results
2. NeurogesX to Report Third Quarter 2008 Financial Results
3. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
4. NeurogesX Responds to EMEAs Day 120 Questions
5. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
6. NeurogesX Reports Second Quarter 2008 Results
7. NeurogesX to Report Second Quarter 2008 Financial Results
8. NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998
9. NeurogesX to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
10. NeurogesX Reports First Quarter 2008 Results
11. NeurogesX to Report First Quarter 2008 Financial Results